Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(4)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05613166Phase 2Unknown

Adjunctive Everolimus Treatment of Refractory Epilepsy

Role: lead

NCT04622748Unknown

Neurocognitive Functions of Recovered COVID-19 Patients

Role: lead

NCT04349748Not ApplicableUnknown

MHealth Intervention of HIV and STDs Partner Notification for MSM

Role: lead

NCT04133974Not ApplicableCompleted

Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts

Role: lead

NCT04013464Not ApplicableCompleted

Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

Role: collaborator

NCT01991704Completed

Incubation of Alcohol Craving During Abstinence

Role: lead

NCT01980550Phase 4Completed

Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy

Role: lead

NCT00759005Not ApplicableCompleted

Effect of Stress on Heroin-Related Memory Retrieval

Role: lead

All 8 trials loaded